文献速递肿瘤 PET/CT核素与放射性配体治疗

两种IgG4相关疾病亚型在68Ga-FAPI-04与18F-FDG PET/CT所示纤维炎性活动中的差异

Differences in Fibroinflammatory Activity Shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease.
PubMed 文献 · J Nucl Med · 2025-04-01

研究纳入37例新诊断IgG4相关疾病患者(增殖型29例、纤维型8例),比较68Ga-FAPI-04与18F-FDG PET/CT的摄取及PET指数。增殖型68Ga-FAPI-04摄取显著高于纤维型,而18F-FDG摄取相似;PET指数≥1.5者一线治疗后无复发生存期显著更短。

要点

  • 增殖型IgG4-RD的68Ga-FAPI-04 SUVmax和TBR显著高于纤维型,18F-FDG摄取两组相似。
  • 增殖型PET指数高于纤维型,胰腺胆道病变PET指数显著高于头颈、纤维化或主动脉炎、淋巴结及其他亚型。
  • 一线治疗后PET指数≥1.5者无复发生存期显著短于<1.5者(22.0个月 vs 未达到)。

核心结论

  • 增殖型IgG4-RD的纤维炎性活动权重高于纤维型。
  • PET指数作为纤维炎性活动权重的标志物,可预测IgG4-RD的无复发生存期。

研究设计与样本

  • 纳入37例新诊断IgG4-RD患者,其中增殖型29例、纤维型8例,均行68Ga-FAPI-04和18F-FDG PET/CT。
  • 测量IgG4-RD病灶的SUVmax和靶本比(TBR),计算病灶PET指数为68Ga-FAPI-04与18F-FDG的SUVmax或TBR之商。
  • 个体全局PET指数定义为所有受累病灶68Ga-FAPI-04 PET/CT的SUVmean与18F-FDG的SUVmean之比。

主要发现

  • 增殖型与纤维型最显著病灶的18F-FDG摄取相似。
  • 增殖型68Ga-FAPI-04摄取显著高于纤维型:SUVmax 17.67 ± 7.46 vs 10.93 ± 2.22,P = 0.005;TBR 15.49 ± 8.23 vs 9.25 ± 3.00,P = 0.015。
  • 增殖型患者PET指数高于纤维型患者:1.46 ± 0.41 vs 1.14 ± 0.39,P = 0.039。
  • 胰腺胆道病变的PET指数显著高于头颈病变、纤维化或主动脉炎、淋巴结及其他疾病亚型(P < 0.05)。
  • 一线治疗后,PET指数≥1.5者无复发生存期显著短于PET指数<1.5者:22.0个月 vs 未达到,P < 0.0001;风险比13.46,95%CI 2.236-81.03。

关键数值与推荐

  • 增殖型 vs 纤维型68Ga-FAPI-04 SUVmax:17.67 ± 7.46 vs 10.93 ± 2.22(P = 0.005)。
  • 增殖型 vs 纤维型68Ga-FAPI-04 TBR:15.49 ± 8.23 vs 9.25 ± 3.00(P = 0.015)。
  • 增殖型 vs 纤维型PET指数:1.46 ± 0.41 vs 1.14 ± 0.39(P = 0.039)。
  • PET指数≥1.5 vs <1.5者无复发生存期:22.0个月 vs 未达到(P < 0.0001;HR 13.46,95%CI 2.236-81.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IgG4-related disease (IgG4-RD) is a highly heterogeneous autoimmune disease. Recently, 2 subtypes of IgG4-RD, proliferative and fibrotic, were defined according to patients' clinicopathologic characteristics. The purpose of this study was to determine the difference in fibroinflammatory activity shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the proliferative and fibrotic IgG4-RD subtypes. Methods: Thirty-seven newly diagnosed IgG4-RD patients (29 of the proliferative subtype and 8 of the fibrotic subtype) who had undergone 68Ga-FAPI-04 and 18F-FDG PET/CT were enrolled. SUVmax and target-to-background ratio (TBR) of IgG4-RD lesions were measured. To evaluate the weight of fibroinflammatory activity, the PET index of a lesion was calculated as the quotient of SUVmax or TBR of 68Ga-FAPI-04 and that of 18F-FDG. For the assessment of the global disease in an individual patient, the PET index was defined as the ratio of SUVmean of all involved lesions in 68Ga-FAPI-04 PET/CT to that in 18F-FDG. Results: The 18F-FDG uptake values of the most prominent lesions in the proliferative and fibrotic subtypes were similar; however, the proliferative subtype showed significantly higher uptake of 68Ga-FAPI-04 than did the fibrotic subtype (SUVmax, 17.67 ± 7.46 vs. 10.93 ± 2.22, P = 0.005; TBR, 15.49 ± 8.23 vs. 9.25 ± 3.00, P = 0.015). The PET index of proliferative-subtype patients was higher than that of fibrotic-subtype patients (1.46 ± 0.41 vs. 1.14 ± 0.39, P = 0.039). The PET index of pancreatobiliary disease was significantly higher than that of head-and-neck disease, fibrosis or aortitis, lymph nodes, and another disease subtype (P < 0.05). After first-line treatment, patients with a PET index of at least 1.5 had significantly shorter relapse-free survival than those with a PET index of less than 1.5 (22.0 mo vs. not reached, P < 0.0001; hazard ratio, 13.46; 95% CI, 2.236-81.03). Conclusion: The proliferative subtype of IgG4-RD had a greater weight of fibroinflammatory activity than that of the fibrotic subtype. The PET index, a marker of the weight of fibroinflammatory activity, is predictive of relapse-free survival of IgG4-RD.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu S, Pan Q, Zhang H, et al. Differences in Fibroinflammatory Activity Shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease. J Nucl Med. 2025. PMID: 40049749. doi:10.2967/jnumed.124.268943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。